Edgewise Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Edgewise Therapeutics (NASDAQ:EWTX) reported Q3 earnings, missing estimated earnings by 2.5% with an EPS of $-0.41 versus an estimate of $-0.4. Revenue was down $0 from the same period last year. Last quarter, the company beat EPS estimates by $0.06, followed by a 0.45% drop in share price.
November 09, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edgewise Therapeutics' Q3 earnings missed estimates, which could negatively impact the stock price.
Edgewise Therapeutics reported lower than expected earnings for Q3. This could lead to a decrease in investor confidence and a potential drop in the stock price, as was seen last quarter when the company beat EPS estimates but the share price dropped by 0.45% the next day.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100